1. Market Research
  2. > Eye Infections - Pipeline Review, H1 2013

Eye Infections - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 50 pages

Eye Infections - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Eye Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Eye Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eye Infections. Eye Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Eye Infections.
- A review of the Eye Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Eye Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Eye Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Eye Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Eye Infections - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eye Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Eye Infections 8
Eye Infections Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Eye Infections Therapeutics - Products under Development by Companies 15
Companies Involved in Eye Infections Therapeutics Development 16
Bausch and Lomb Incorporated 16
InSite Vision Incorporated 17
NanoViricides, Inc. 18
Foamix Ltd. 19
Redox Pharmaceutical Corporation 20
Sirnaomics, Inc. 21
SIFI Pharma 22
Dompe Farmaceutici S.p.A. 23
Altacor Ltd. 24
Icon Bioscience, Inc. 25
Eye Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
azithromycin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
CTC-96 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SF-111 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
SF-101 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
SF-105 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
EKCCide-I - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
(tobramycin + prednisolone acetate) - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
tetracycline - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
STP-601 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
AGN-195263 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
ALT-005 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
dexamethasone acetate + Antibiotic - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Eye Infections Therapeutics - Drug Profile Updates 45
Eye Infections Therapeutics - Discontinued Products 46
Eye Infections Therapeutics - Dormant Products 47
Eye Infections - Product Development Milestones 48
Featured News and Press Releases 48
May 10, 2012: Researchers Present Preclinical Data Of Peregrine Pharma's PGN632 At ARVO 2012 48
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables


Number of Products Under Development for Eye Infections, H1 2013 8
Products under Development for Eye Infections - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Bausch and Lomb Incorporated, H1 2013 16
InSite Vision Incorporated, H1 2013 17
NanoViricides, Inc., H1 2013 18
Foamix Ltd., H1 2013 19
Redox Pharmaceutical Corporation, H1 2013 20
Sirnaomics, Inc., H1 2013 21
SIFI Pharma, H1 2013 22
Altacor Ltd., H1 2013 24
Icon Bioscience, Inc., H1 2013 25
Assessment by Monotherapy Products, H1 2013 26
Assessment by Combination Products, H1 2013 27
Assessment by Stage and Route of Administration, H1 2013 29
Assessment by Stage and Molecule Type, H1 2013 31
Eye Infections Therapeutics - Drug Profile Updates 45
Eye Infections Therapeutics - Discontinued Products 46
Eye Infections Therapeutics - Dormant Products 47

List of Figures


Number of Products under Development for Eye Infections, H1 2013 8
Products under Development for Eye Infections - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Discovery and Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 26
Assessment by Combination Products, H1 2013 27
Assessment by Route of Administration, H1 2013 28
Assessment by Stage and Route of Administration, H1 2013 29
Assessment by Molecule Type, H1 2013 30
Assessment by Stage and Molecule Type, H1 2013 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.